{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:15:35Z","timestamp":1791900935445,"version":"4.3.4"},"reference-count":90,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2018,11,27]],"date-time":"2018-11-27T00:00:00Z","timestamp":1543276800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000894","name":"SMA Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000894","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Scholar Rock to Myologica LLC"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,4,1]]},"DOI":"10.1093\/hmg\/ddy382","type":"journal-article","created":{"date-parts":[[2018,11,7]],"date-time":"2018-11-07T20:09:49Z","timestamp":1541621389000},"page":"1076-1089","source":"Crossref","is-referenced-by-count":108,"title":["Specific inhibition of myostatin activation is beneficial in mouse models of SMA therapy"],"prefix":"10.1093","volume":"28","author":[{"given":"Kimberly K","family":"Long","sequence":"first","affiliation":[{"name":"Scholar Rock Inc., 620 Memorial Drive, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen M","family":"O\u2019Shea","sequence":"additional","affiliation":[{"name":"Myologica, 10811 Dewey Way East, New Market, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramzi J","family":"Khairallah","sequence":"additional","affiliation":[{"name":"Myologica, 10811 Dewey Way East, New Market, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Howell","sequence":"additional","affiliation":[{"name":"SMA Foundation, 888 7th Avenue #400, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Paushkin","sequence":"additional","affiliation":[{"name":"SMA Foundation, 888 7th Avenue #400, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen S","family":"Chen","sequence":"additional","affiliation":[{"name":"SMA Foundation, 888 7th Avenue #400, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun M","family":"Cote","sequence":"additional","affiliation":[{"name":"Scholar Rock Inc., 620 Memorial Drive, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micah T","family":"Webster","sequence":"additional","affiliation":[{"name":"Scholar Rock Inc., 620 Memorial Drive, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph P","family":"Stains","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, University of Maryland School of Medicine, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Treece","sequence":"additional","affiliation":[{"name":"Scholar Rock Inc., 620 Memorial Drive, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Buckler","sequence":"additional","affiliation":[{"name":"Scholar Rock Inc., 620 Memorial Drive, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Donovan","sequence":"additional","affiliation":[{"name":"Scholar Rock Inc., 620 Memorial Drive, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,11,27]]},"reference":[{"key":"key\n\t\t\t\t2019031903270003100_ref1","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1007\/s13311-014-0293-y","article-title":"Spinal muscular atrophy: journeying from bench to bedside","volume":"11","author":"Awano","year":"2014","journal-title":"Neurotherapeutics"},{"key":"key\n\t\t\t\t2019031903270003100_ref2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/ejhg.2011.134","article-title":"Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72,400 specimens","volume":"20","author":"Sugarman","year":"2012","journal-title":"Eur. J. Hum. Genet."},{"key":"key\n\t\t\t\t2019031903270003100_ref3","first-page":"235","article-title":"Neurogenic disorders","author":"Dubowitz","year":"2013"},{"key":"key\n\t\t\t\t2019031903270003100_ref4","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.neuron.2005.12.001","article-title":"Spinal muscular atrophy: a deficiency in a ubiquitous protein; a motor neuron-specific disease","volume":"48","author":"Monani","year":"2005","journal-title":"Neuron"},{"key":"key\n\t\t\t\t2019031903270003100_ref5","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.nmd.2015.04.009","article-title":"209th ENMC international workshop: outcome measures and clinical trial readiness in spinal muscular atrophy, 7\u20139 November 2014, Heemskerk, The Netherlands","volume":"25","author":"Finkel","year":"2015","journal-title":"Neuromuscul. Disord."},{"key":"key\n\t\t\t\t2019031903270003100_ref6","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"key":"key\n\t\t\t\t2019031903270003100_ref7","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1093\/hmg\/8.7.1177","article-title":"A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2","volume":"8","author":"Monani","year":"1999","journal-title":"Hum. Mol. Genet."},{"key":"key\n\t\t\t\t2019031903270003100_ref8","article-title":"Spinal muscular atrophy: more than a disease of motor neurons?","author":"Nash","year":"2016","journal-title":"Curr. Mol. Med."},{"key":"key\n\t\t\t\t2019031903270003100_ref9","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1093\/hmg\/ddi078","article-title":"SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN","volume":"14","author":"Le","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"key\n\t\t\t\t2019031903270003100_ref10","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1093\/hmg\/dds285","article-title":"Characterization of behavioral and neuromuscular junction phenotypes in a novel allelic series of SMA mouse models","volume":"21","author":"Osborne","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"key\n\t\t\t\t2019031903270003100_ref11","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/hmg\/ddr453","article-title":"Severe neuromuscular denervation of clinically relevant muscles in a mouse model of spinal muscular atrophy","volume":"21","author":"Ling","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"key\n\t\t\t\t2019031903270003100_ref12","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1006\/nbdi.1996.0010","article-title":"The neurobiology of childhood spinal muscular atrophy","volume":"3","author":"Crawford","year":"1996","journal-title":"Neurobiol. Dis."},{"key":"key\n\t\t\t\t2019031903270003100_ref13","first-page":"341","article-title":"Spinal Muscular Atrophy: Disease Mechanisms and Therapy","author":"Le Verche","year":"2017"},{"key":"key\n\t\t\t\t2019031903270003100_ref14","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/ana.20473","article-title":"Natural history of denervation in SMA: relation to age, SMN2 copy number, and function","volume":"57","author":"Swoboda","year":"2005","journal-title":"Ann. Neurol."},{"key":"key\n\t\t\t\t2019031903270003100_ref15","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/path.2566","article-title":"Bone loss in survival motor neuron (Smn(\u2212\/\u2212) SMN2) genetic mouse model of spinal muscular atrophy","volume":"219","author":"Shanmugarajan","year":"2009","journal-title":"J. Pathol."},{"key":"key\n\t\t\t\t2019031903270003100_ref16","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.bone.2015.05.039","article-title":"Bone and spinal muscular atrophy","volume":"79","author":"Vai","year":"2015","journal-title":"Bone"},{"key":"key\n\t\t\t\t2019031903270003100_ref17","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.nmd.2017.01.019","article-title":"Low bone mineral density and fractures are highly prevalent in pediatric patients with spinal muscular atrophy regardless of disease severity","volume":"27","author":"Wasserman","year":"2017","journal-title":"Neuromuscul. Disord."},{"key":"key\n\t\t\t\t2019031903270003100_ref18","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"key\n\t\t\t\t2019031903270003100_ref19","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1172\/JCI41615","article-title":"CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy","volume":"120","author":"Passini","year":"2010","journal-title":"J. Clin. Invest."},{"key":"key\n\t\t\t\t2019031903270003100_ref20","article-title":"AVXS-101 trial experience: CHOP-INTEND effectively quantifies early, rapid, and sustained improvements that precede subsequent milestone achievement but is not sensitive to continued advances in motor function in infants with SMA type 1.","author":"Lowes","year":"2018"},{"key":"key\n\t\t\t\t2019031903270003100_ref21","doi-asserted-by":"crossref","first-page":"10067","DOI":"10.1021\/acs.jmedchem.6b00670","article-title":"Small molecules in development for the treatment of spinal muscular atrophy","volume":"59","author":"Calder","year":"2016","journal-title":"J. Med. Chem."},{"key":"key\n\t\t\t\t2019031903270003100_ref22","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1126\/science.1250127","article-title":"Motor neuron disease. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy","volume":"345","author":"Naryshkin","year":"2014","journal-title":"Science"},{"key":"key\n\t\t\t\t2019031903270003100_ref23","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/nchembio.1837","article-title":"SMN2 splice modulators enhance U1-pre-mRNA association and rescue SMA mice","volume":"11","author":"Palacino","year":"2015","journal-title":"Nat. Chem. Biol."},{"key":"key\n\t\t\t\t2019031903270003100_ref24","doi-asserted-by":"crossref","first-page":"6086","DOI":"10.1021\/acs.jmedchem.6b00459","article-title":"Specific correction of alternative survival motor neuron 2 splicing by small molecules: discovery of a potential novel medicine to treat spinal muscular atrophy","volume":"59","author":"Ratni","year":"2016","journal-title":"J. Med. Chem."},{"key":"key\n\t\t\t\t2019031903270003100_ref25","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","article-title":"Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy","volume":"86","author":"Chiriboga","year":"2016","journal-title":"Neurology"},{"key":"key\n\t\t\t\t2019031903270003100_ref26","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study","volume":"388","author":"Finkel","year":"2016","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019031903270003100_ref27","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"key\n\t\t\t\t2019031903270003100_ref28","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1101\/gad.1941310","article-title":"Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model","volume":"24","author":"Hua","year":"2010","journal-title":"Genes Dev."},{"key":"key\n\t\t\t\t2019031903270003100_ref29","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nature10485","article-title":"Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model","volume":"478","author":"Hua","year":"2011","journal-title":"Nature"},{"key":"key\n\t\t\t\t2019031903270003100_ref30","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001777","article-title":"Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy","volume":"3","author":"Passini","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"key\n\t\t\t\t2019031903270003100_ref31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1515\/tnsci-2017-0001","article-title":"ISS-N1 makes the First FDA-approved Drug for Spinal Muscular Atrophy","volume":"8","author":"Ottesen","year":"2017","journal-title":"Transl. Neurosci."},{"key":"key\n\t\t\t\t2019031903270003100_ref32","author":"FDA, memorandum","year":"2016"},{"key":"key\n\t\t\t\t2019031903270003100_ref33","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus Sham Control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"key\n\t\t\t\t2019031903270003100_ref34","first-page":"S109","volume-title":"23rd World Muscle Society Congress, Mendoza, Argentina.","author":"Baranello","year":"2018"},{"key":"key\n\t\t\t\t2019031903270003100_ref35","volume-title":"22nd Annual Spinal Muscular Atrophy Researcher Meeting, Dallas, TX.","author":"Vivo","year":"2018"},{"key":"key\n\t\t\t\t2019031903270003100_ref36","volume":"28","author":"Mendell","year":"2018","journal-title":"23rd World Muscle Society Congress, Mendoza, Argentina."},{"key":"key\n\t\t\t\t2019031903270003100_ref37","first-page":"S108","volume":"28","author":"Mercuri","year":"2018","journal-title":"23rd World Muscle Society Congress, Mendoza, Argentina."},{"key":"key\n\t\t\t\t2019031903270003100_ref38","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1093\/hmg\/ddv629","article-title":"Pharmacologically induced mouse model of adult spinal muscular atrophy to evaluate effectiveness of therapeutics after disease onset","volume":"25","author":"Feng","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"key\n\t\t\t\t2019031903270003100_ref39","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/387083a0","article-title":"Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member","volume":"387","author":"McPherron","year":"1997","journal-title":"Nature"},{"key":"key\n\t\t\t\t2019031903270003100_ref40","doi-asserted-by":"crossref","first-page":"12457","DOI":"10.1073\/pnas.94.23.12457","article-title":"Double muscling in cattle due to mutations in the myostatin gene","volume":"94","author":"McPherron","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U.\u00a0S.\u00a0A."},{"key":"key\n\t\t\t\t2019031903270003100_ref41","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1371\/journal.pgen.0030079","article-title":"A mutation in the myostatin gene increases muscle mass and enhances racing performance in heterozygote dogs","volume":"3","author":"Mosher","year":"2007","journal-title":"PLoS Genet."},{"key":"key\n\t\t\t\t2019031903270003100_ref42","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa040933","article-title":"Myostatin mutation associated with gross muscle hypertrophy in a child","volume":"350","author":"Schuelke","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"key\n\t\t\t\t2019031903270003100_ref43","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13395-015-0060-8","article-title":"Myostatin blockade with a fully human monoclonal antibody induces muscle hypertrophy and reverses muscle atrophy in young and aged mice","volume":"5","author":"Latres","year":"2015","journal-title":"Skelet. Muscle"},{"key":"key\n\t\t\t\t2019031903270003100_ref44","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1158\/1535-7163.MCT-14-0681","article-title":"Myostatin neutralization results in preservation of muscle mass and strength in preclinical models of tumor-induced muscle wasting","volume":"14","author":"Smith","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"key\n\t\t\t\t2019031903270003100_ref45","doi-asserted-by":"crossref","DOI":"10.1097\/PHM.0000000000000617","article-title":"Reloading promotes recovery of disuse muscle loss by inhibiting TGFbeta pathway activation in rats after hind limb suspension","author":"Wang","year":"2017","journal-title":"Am. J. Phys. Med. Rehabil."},{"key":"key\n\t\t\t\t2019031903270003100_ref46","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.cell.2010.07.011","article-title":"Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival","volume":"142","author":"Zhou","year":"2010","journal-title":"Cell"},{"key":"key\n\t\t\t\t2019031903270003100_ref47","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2174\/187152210793663748","article-title":"Extracellular Regulation of Myostatin: A molecular rheostat for muscle mass","volume":"10","author":"Lee","year":"2010","journal-title":"Immunol. Endocr. Metab. Agents Med. Chem."},{"key":"key\n\t\t\t\t2019031903270003100_ref48","doi-asserted-by":"crossref","first-page":"9306","DOI":"10.1073\/pnas.151270098","article-title":"Regulation of myostatin activity and muscle growth","volume":"98","author":"Lee","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U.\u00a0S.\u00a0A."},{"key":"key\n\t\t\t\t2019031903270003100_ref49","doi-asserted-by":"crossref","first-page":"15842","DOI":"10.1073\/pnas.2534946100","article-title":"Activation of latent myostatin by the BMP-1\/tolloid family of metalloproteinases","volume":"100","author":"Wolfman","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.\u00a0S.\u00a0A."},{"key":"key\n\t\t\t\t2019031903270003100_ref50","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.biocel.2013.05.019","article-title":"Myostatin\/activin pathway antagonism: molecular basis and therapeutic potential","volume":"45","author":"Han","year":"2013","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"key\n\t\t\t\t2019031903270003100_ref51","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/nbt.3557","article-title":"No longer going to waste","volume":"34","author":"Garber","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"key\n\t\t\t\t2019031903270003100_ref52","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1212\/WNL.0000000000001070","article-title":"Treatment of sporadic inclusion body myositis with bimagrumab","volume":"83","author":"Amato","year":"2014","journal-title":"Neurology"},{"key":"key\n\t\t\t\t2019031903270003100_ref53","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S2213-8587(15)00298-3","article-title":"Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial","volume":"3","author":"Becker","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"key":"key\n\t\t\t\t2019031903270003100_ref54","article-title":"Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial","author":"Campbell","year":"2016","journal-title":"Muscle Nerve"},{"key":"key\n\t\t\t\t2019031903270003100_ref55","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/mt.2014.200","article-title":"A phase 1\/2a follistatin gene therapy trial for becker muscular dystrophy","volume":"23","author":"Mendell","year":"2015","journal-title":"Mol. Ther."},{"key":"key\n\t\t\t\t2019031903270003100_ref56","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/ana.21338","article-title":"A phase I\/IItrial of MYO-029 in adult subjects with muscular dystrophy","volume":"63","author":"Wagner","year":"2008","journal-title":"Ann. Neurol."},{"key":"key\n\t\t\t\t2019031903270003100_ref57","doi-asserted-by":"crossref","first-page":"18117","DOI":"10.1073\/pnas.0505996102","article-title":"Regulation of muscle growth by multiple ligands signaling through activin type II receptors","volume":"102","author":"Lee","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.\u00a0S.\u00a0A."},{"key":"key\n\t\t\t\t2019031903270003100_ref58","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13395-017-0141-y","article-title":"A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys","volume":"7","author":"St Andre","year":"2017","journal-title":"Skelet. Muscle"},{"key":"key\n\t\t\t\t2019031903270003100_ref59","doi-asserted-by":"crossref","DOI":"10.1111\/cen.13601","article-title":"Effects of bimagrumab, an activin receptor type II inhibitor, on pituitary neurohormonal axes","author":"Garito","year":"2018","journal-title":"Clin. Endocrinol."},{"key":"key\n\t\t\t\t2019031903270003100_ref60","article-title":"Activin receptor Type IIB Inhibition Improves Muscle Phenotype and Function in a Mouse Model of Spinal Muscular Atrophy","volume":"11","author":"Liu","year":"2016","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t2019031903270003100_ref61","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1093\/hmg\/ddp253","article-title":"Inhibition of myostatin does not ameliorate disease features of severe spinal muscular atrophy mice","volume":"18","author":"Sumner","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"key\n\t\t\t\t2019031903270003100_ref62","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/hmg\/ddn426","article-title":"Delivery of recombinant follistatin lessens disease severity in a mouse model of spinal muscular atrophy","volume":"18","author":"Rose","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"key\n\t\t\t\t2019031903270003100_ref63","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1210\/en.2008-0259","article-title":"Differential antagonism of activin, myostatin and growth and differentiation factor 11 by wild-type and mutant follistatin","volume":"149","author":"Schneyer","year":"2008","journal-title":"Endocrinology"},{"key":"key\n\t\t\t\t2019031903270003100_ref64","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3109\/08977190109029114","article-title":"GDF-8 propeptide binds to GDF-8 and antagonizes biological activity by inhibiting GDF-8 receptor binding","volume":"18","author":"Thies","year":"2001","journal-title":"Growth Factors"},{"key":"key\n\t\t\t\t2019031903270003100_ref65","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1038\/s41598-018-20524-9","article-title":"Blocking extracellular activation of myostatin as a strategy for treating muscle wasting","volume":"8","author":"Pirruccello-Straub","year":"2018","journal-title":"Sci. Rep."},{"key":"key\n\t\t\t\t2019031903270003100_ref66","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1093\/hmg\/ddw062","article-title":"Pharmacokinetics, pharmacodynamics, and efficacy of a small-molecule SMN2 splicing modifier in mouse models of spinal muscular atrophy","volume":"25","author":"Zhao","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"key\n\t\t\t\t2019031903270003100_ref67","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1096\/fj.10-176917","article-title":"Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease","volume":"25","author":"Zhang","year":"2011","journal-title":"FASEB J."},{"key":"key\n\t\t\t\t2019031903270003100_ref68","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1093\/hmg\/ddn156","article-title":"Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of spinal muscular atrophy","volume":"17","author":"Kariya","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"key\n\t\t\t\t2019031903270003100_ref69","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1523\/JNEUROSCI.4434-08.2009","article-title":"Impaired synaptic vesicle release and immaturity of neuromuscular junctions in spinal muscular atrophy mice","volume":"29","author":"Kong","year":"2009","journal-title":"J. Neurosci."},{"key":"key\n\t\t\t\t2019031903270003100_ref70","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/acn3.23","article-title":"Electrophysiological biomarkers in spinal muscular atrophy: preclinical proof of concept","volume":"1","author":"Arnold","year":"2014","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"key\n\t\t\t\t2019031903270003100_ref71","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/nm.3917","article-title":"Myostatin is a direct regulator of osteoclast differentiation and its inhibition reduces inflammatory joint destruction in mice","volume":"21","author":"Dankbar","year":"2015","journal-title":"Nat. Med."},{"key":"key\n\t\t\t\t2019031903270003100_ref72","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.bone.2017.01.032","article-title":"Administration of an activin receptor IIB ligand trap protects male juvenile rhesus macaques from simian immunodeficiency virus-associated bone loss","volume":"97","author":"Guo","year":"2017","journal-title":"Bone"},{"key":"key\n\t\t\t\t2019031903270003100_ref73","doi-asserted-by":"crossref","first-page":"9878","DOI":"10.1038\/s41598-017-10404-z","article-title":"Inhibition of GDF8 (Myostatin) accelerates bone regeneration in diabetes mellitus type 2","volume":"7","author":"Wallner","year":"2017","journal-title":"Sci. Rep."},{"key":"key\n\t\t\t\t2019031903270003100_ref74","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1016\/j.bone.2007.02.012","article-title":"Loss of myostatin (GDF8) function increases osteogenic differentiation of bone marrow-derived mesenchymal stem cells but the osteogenic effect is ablated with unloading","volume":"40","author":"Hamrick","year":"2007","journal-title":"Bone"},{"key":"key\n\t\t\t\t2019031903270003100_ref75","doi-asserted-by":"crossref","first-page":"4289","DOI":"10.1210\/en.2010-0134","article-title":"A soluble activin receptor type IIb prevents the effects of androgen deprivation on body composition and bone health","volume":"151","author":"Koncarevic","year":"2010","journal-title":"Endocrinology"},{"key":"key\n\t\t\t\t2019031903270003100_ref76","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00198-015-3226-7","article-title":"Myostatin deficiency partially rescues the bone phenotype of osteogenesis imperfecta model mice","volume":"27","author":"Oestreich","year":"2016","journal-title":"Osteoporos. Int."},{"key":"key\n\t\t\t\t2019031903270003100_ref77","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00415-016-8379-6","article-title":"Reduced serum myostatin concentrations associated with genetic muscle disease progression","volume":"264","author":"Burch","year":"2017","journal-title":"J. Neurol."},{"key":"key\n\t\t\t\t2019031903270003100_ref78","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41467-017-01486-4","article-title":"Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches","volume":"8","author":"Mariot","year":"2017","journal-title":"Nat. Commun."},{"key":"key\n\t\t\t\t2019031903270003100_ref79","doi-asserted-by":"crossref","first-page":"7027","DOI":"10.1074\/jbc.M706678200","article-title":"Identification of a novel pool of extracellular pro-myostatin in skeletal muscle","volume":"283","author":"Anderson","year":"2008","journal-title":"J. Biol. Chem."},{"key":"key\n\t\t\t\t2019031903270003100_ref80","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/0167-5699(95)80161-8","article-title":"Cytokine-binding proteins: stimulating antagonists","volume":"16","author":"Klein","year":"1995","journal-title":"Immunol. Today"},{"key":"key\n\t\t\t\t2019031903270003100_ref81","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1002\/jcph.357","article-title":"Utility of free and total target measurements as target engagement and efficacy biomarkers in biotherapeutic development\u2014opportunities and challenges","volume":"55","author":"Zheng","year":"2015","journal-title":"J. Clin. Pharmacol."},{"key":"key\n\t\t\t\t2019031903270003100_ref82","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.bone.2013.12.002","article-title":"A myostatin and activin decoy receptor enhances bone formation in mice","volume":"60","author":"Bialek","year":"2014","journal-title":"Bone"},{"key":"key\n\t\t\t\t2019031903270003100_ref83","doi-asserted-by":"crossref","first-page":"6160","DOI":"10.1093\/hmg\/ddv332","article-title":"Low levels of Survival Motor Neuron protein are sufficient for normal muscle function in the SMN\u03947 mouse model of SMA","volume":"24","author":"Iyer","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"key\n\t\t\t\t2019031903270003100_ref84","doi-asserted-by":"crossref","first-page":"A1","DOI":"10.1089\/neu.2017.29011.abstracts","article-title":"Pharmacological inhibition of myostatin in a model of spinal cord injury improves key characteristics of muscle pathology. The 35(th) Annual National Neurotrauma Symposium July 7\u201312, 2017, Snowbird, Utah","volume":"34","author":"Bigford","year":"2017","journal-title":"J. Neurotrauma"},{"key":"key\n\t\t\t\t2019031903270003100_ref85","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1089\/neu.2015.4058","article-title":"A soluble activin receptor IIB fails to prevent muscle atrophy in a mouse model of spinal cord injury","volume":"33","author":"Graham","year":"2016","journal-title":"J. Neurotrauma"},{"key":"key\n\t\t\t\t2019031903270003100_ref86","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1126\/science.7973664","article-title":"GDNF: a potent survival factor for motoneurons present in peripheral nerve and muscle","volume":"266","author":"Henderson","year":"1994","journal-title":"Science"},{"key":"key\n\t\t\t\t2019031903270003100_ref87","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1242\/dev.124.15.2903","article-title":"Hepatocyte growth factor (HGF\/SF) is a muscle-derived survival factor for a subpopulation of embryonic motoneurons","volume":"124","author":"Yamamoto","year":"1997","journal-title":"Development"},{"key":"key\n\t\t\t\t2019031903270003100_ref88","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1152\/japplphysiol.00874.2015","article-title":"Paracrine and endocrine modes of myostatin action","volume":"120","author":"Lee","year":"2016","journal-title":"J. Appl. Physiol. (1985)"},{"key":"key\n\t\t\t\t2019031903270003100_ref89","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1002\/jbmr.141","article-title":"Guidelines for assessment of bone microstructure in rodents using micro-computed tomography","volume":"25","author":"Bouxsein","year":"2010","journal-title":"J. Bone Miner Res."},{"key":"key\n\t\t\t\t2019031903270003100_ref90","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.mce.2008.12.019","article-title":"Measurement of myostatin concentrations in human serum: circulating concentrations in young and older men and effects of testosterone administration","volume":"302","author":"Lakshman","year":"2009","journal-title":"Mol. Cell. Endocrinol."}],"container-title":["Human Molecular Genetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/hmg\/article-pdf\/28\/7\/1076\/28073461\/ddy382.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T15:03:43Z","timestamp":1662390223000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/hmg\/article\/28\/7\/1076\/5194088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,27]]},"references-count":90,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2018,11,27]]},"published-print":{"date-parts":[[2019,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/hmg\/ddy382","relation":{},"ISSN":["0964-6906","1460-2083"],"issn-type":[{"value":"0964-6906","type":"print"},{"value":"1460-2083","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,4,1]]},"published":{"date-parts":[[2018,11,27]]}}}